Zymride M 3 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The prolonged-release formulation of this tablet ensures a steady release of active ingredients, promoting sustained blood glucose regulation and improved patient compliance. Zymride M 3 Forte is indicated for patients inadequately controlled on diet and exercise alone or those not achieving glycemic targets with monotherapy. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and weight gain. This medication should be used under medical supervision, with lifestyle modifications to optimize diabetes management and reduce the risk of complications associated with chronic hyperglycemia.